Full Press Release Details
CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS.
CRSP
CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS
Key Takeaway: CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension